| Primary |
| Product Used For Unknown Indication |
26.0% |
| Surgery |
14.0% |
| Hypovolaemia |
12.0% |
| Anaesthesia |
10.0% |
| Fluid Replacement |
6.0% |
| Postpartum Haemorrhage |
6.0% |
| Sepsis |
4.0% |
| Vascular Graft |
4.0% |
| Haemodilution |
2.0% |
| Hypovolemia |
2.0% |
| Induction And Maintenance Of Anaesthesia |
2.0% |
| Induction Of Anaesthesia |
2.0% |
| Operative Haemorrhage |
2.0% |
| Placenta Praevia Haemorrhage |
2.0% |
| Procedural Haemorrhage |
2.0% |
| Septic Shock |
2.0% |
| Tachycardia |
2.0% |
|
| Respiratory Failure |
14.8% |
| Hypotension |
11.1% |
| Toxic Epidermal Necrolysis |
7.4% |
| Ventricular Dysfunction |
7.4% |
| Anaphylactic Reaction |
3.7% |
| Anastomotic Complication |
3.7% |
| Angioedema |
3.7% |
| Arrhythmia |
3.7% |
| Bronchospasm |
3.7% |
| Crime |
3.7% |
| Hypersensitivity |
3.7% |
| Joint Contracture |
3.7% |
| Maternal Drugs Affecting Foetus |
3.7% |
| Obstructive Airways Disorder |
3.7% |
| Procedural Haemorrhage |
3.7% |
| Rash |
3.7% |
| Renal Failure Chronic |
3.7% |
| Renal Tubular Disorder |
3.7% |
| Respiratory Disorder |
3.7% |
| Shock Haemorrhagic |
3.7% |
|
| Secondary |
| Hypertension |
12.0% |
| Supplementation Therapy |
11.6% |
| Product Used For Unknown Indication |
8.5% |
| Psoas Abscess |
8.5% |
| Pain |
7.7% |
| Vascular Operation |
7.0% |
| Fluid Replacement |
5.4% |
| General Anaesthesia |
5.0% |
| Hyperglycaemia |
4.1% |
| Prophylaxis |
3.9% |
| Thrombosis Prophylaxis |
3.5% |
| Secretion Discharge |
3.3% |
| Drug Exposure During Pregnancy |
2.9% |
| Hypotension |
2.7% |
| Restlessness |
2.7% |
| Postpartum Haemorrhage |
2.5% |
| Tocolysis |
2.5% |
| Antibiotic Prophylaxis |
2.1% |
| Polyuria |
2.1% |
| Stridor |
2.1% |
|
| Anaphylactoid Shock |
10.5% |
| Generalised Erythema |
10.5% |
| Stevens-johnson Syndrome |
10.5% |
| Intra-uterine Death |
7.9% |
| Tongue Oedema |
7.9% |
| Renal Tubular Necrosis |
5.3% |
| Tachycardia |
5.3% |
| Thrombocytopenia |
5.3% |
| Toxic Epidermal Necrolysis |
5.3% |
| Type I Hypersensitivity |
5.3% |
| Anaphylactic Reaction |
2.6% |
| Drug Administration Error |
2.6% |
| Escherichia Test Positive |
2.6% |
| Heparin-induced Thrombocytopenia |
2.6% |
| Lactic Acidosis |
2.6% |
| Medication Error |
2.6% |
| Palatal Oedema |
2.6% |
| Premature Baby |
2.6% |
| Pruritus |
2.6% |
| Renal Failure |
2.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
12.5% |
| Sedation |
12.5% |
| Prophylaxis |
7.3% |
| Haemodynamic Instability |
6.6% |
| Drug Use For Unknown Indication |
5.7% |
| Infection |
4.7% |
| Supplementation Therapy |
4.7% |
| Hypovolaemia |
4.6% |
| Prophylaxis Against Gastrointestinal Ulcer |
4.6% |
| Oliguria |
4.4% |
| Positive Cardiac Inotropic Effect |
4.4% |
| Pain |
3.9% |
| Pain Prophylaxis |
3.8% |
| Hypertension |
3.6% |
| Diffuse Large B-cell Lymphoma |
3.2% |
| Intensive Care |
3.0% |
| Vasoplegia Syndrome |
2.8% |
| Parenteral Nutrition |
2.6% |
| Anaesthesia |
2.5% |
| Hypotension |
2.5% |
|
| Haematemesis |
15.0% |
| Rectal Haemorrhage |
15.0% |
| Sepsis |
11.3% |
| Urticaria |
8.8% |
| Sinusitis |
7.5% |
| Septic Shock |
5.0% |
| General Physical Health Deterioration |
3.8% |
| Meningitis Pneumococcal |
3.8% |
| Abdominal Pain |
2.5% |
| Abscess |
2.5% |
| Colitis Ulcerative |
2.5% |
| Dialysis |
2.5% |
| Myocardial Infarction |
2.5% |
| Pleural Effusion |
2.5% |
| Pruritus |
2.5% |
| Rash |
2.5% |
| Rash Erythematous |
2.5% |
| Renal Failure Acute |
2.5% |
| Toxic Epidermal Necrolysis |
2.5% |
| Urinary Tract Infection |
2.5% |
|
